Despite a recent boost in China Resources Double-Crane Pharm...

Despite a recent boost in China Resources Double-Crane Pharmaceutical's stock, its low P/E ratio suggests investors expect limited future growth. The company's forecast growth is lower than the wider market, indicating a potential lack of strong share price rise in the near future.